咖啡因通过抑制-H2AX的形成来限制乙型肝炎病毒的转录
Fangli Liao1, Siyi Sun1, Wenjuan Huang2
1Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in microbiology
|November 26, 2025
概括
摄入咖啡因可以通过减少DNA损伤标志物gamma-H2AX.抑制乙型肝炎病毒 (HBV). 这一发现表明,gamma-H2AX是通过饮食来控制HBV感染的目标.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
- 病毒学 病毒学
背景情况:
- 咖啡因对健康的影响已知,但其对乙型肝炎病毒 (HBV) 的影响尚不清楚.
- 肝瘤细胞用于研究HBV复制和潜在的治疗干预措施.
研究的目的:
- 为了研究外源咖啡因对乙型肝炎病毒 (HBV) 在肝瘤细胞中复制的影响.
- 阐明咖啡因对HBV基因表达的影响背后的分子机制.
主要方法:
- 用咖啡因对肝瘤细胞进行治疗,以评估HBVRNA和核心蛋白质水平.
- 对DNA损伤标志物gamma-H2AX进行了定量分析.
- 功能测定和染色质免疫沉被用来研究马-H2AX,PPARα和HBV核心促进体之间的相互作用.
主要成果:
- 外源咖啡因显著抑制了HBVRNA和核心蛋白质的表达.
- 咖啡因降低了DNA损伤标记物gamma-H2AX的水平,导致HBV转录减少.
- 发现Gamma-H2AX通过招募PPARα来增强HBV核心促进活性;咖啡因破坏了这种相互作用.
结论:
- 一个涉及马-H2AX和PPARα的信号轴促进HBV转录.
- 咖啡因干扰这种途径,为HBV管理提供了潜在的治疗策略.
- 玛-H2AX代表了辅助HBV治疗的营养目标节点.
相关概念视频
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
463
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
463
Hepatic Drug Excretion: Enterohepatic Cycling
2.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.6K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241


